Physician profile
Kaitlin Sullivan
NPI 1710238001
$2,688.25
in general payments reported to CMS, 2019-2025
35 companies · $465 in 2025
The $465 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $333 · 2022: $834 · 2023: $367 · 2024: $690 · 2025: $465.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,521.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,521.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $408.69 | 2021-2025 | |
| Mayne Pharma Commercial LLC | $303.33 | 2021-2025 | |
| Exeltis, USA INC. | $218.72 | 2022-2025 | Slynd |
| Astellas Pharma US INC | $179.46 | 2021-2025 | Veozah |
| Shield Therapeutics INC | $179.16 | 2023-2025 | Accrufer |
| Biogen, INC. | $135.48 | 2024-2025 | Zurzuvae |
| Seqirus USA INC | $97.04 | 2024 | Flucelvax, Fluad |
| Avion Pharmaceuticals | $90.04 | 2021-2023 | Balcoltra |
| Therapeuticsmd, INC. | $88.81 | 2021-2022 | |
| Hologic Sales and Service, LLC | $83.59 | 2022-2025 | Acessa Provu System, Novasure, Aptima |
| Aspira Women'S Health INC | $73.98 | 2022 | |
| Astellas Pharma Global Development | $64.72 | 2024 | Veozah |
| Agile Therapeutics, INC. | $56.54 | 2022 | |
| Sumitomo Pharma America, INC. | $54.81 | 2023-2024 | Myfembree |
| Novo Nordisk INC | $51.02 | 2023-2025 | Wegovy |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $49.06 | 2024-2025 | Cologuard Collection Kit |
| Myovant Sciences INC. | $48.50 | 2021-2022 | |
| Amgen INC. | $46.71 | 2021-2025 | Evenity, Prolia |
| Radius Health, INC. | $40.89 | 2025 | Tymlos |
| Evofem Biosciences, INC. | $40.68 | 2021-2022 | |
| Organon LLC | $38.93 | 2021-2025 | Nexplanon |
| Merck Sharp & Dohme LLC | $35.49 | 2023-2025 | Gardasil 9 |
| Biohaven Pharmaceutical Holding Company LTD. | $31.52 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $31.25 | 2022-2024 | Exparel |
| Millicent US INC | $30.56 | 2025 | Intrarosa |
| Bayer Healthcare Pharmaceuticals INC. | $29.78 | 2023-2025 | |
| Mylan Pharmaceuticals INC. | $28.04 | 2021-2022 | |
| Scynexis, INC. | $27.75 | 2022 | |
| Abbott Laboratories | $24.24 | 2025 | Freestyle Libre 3 |
| Bracco Diagnostics INC. | $21.65 | 2025 | |
| Virtus Pharmaceuticals LLC | $17.69 | 2021 | |
| Pharmacosmos Therapeutics INC. | $15.28 | 2023 | Monoferric |
| Davol INC. | $15.24 | 2024 | |
| Lilly USA, LLC | $14.80 | 2024 | Zepbound |
| Ibsa Pharma INC. | $14.80 | 2024 | Tirosint, Licart |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kaitlin Sullivan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.